Anti-CCP versus anti-Sa antibodies for the diagnosis of RA: Commentay

Nature Clinical Practice Rheumatology

Volumn 3, Issue 2, 2007, Pages 76-77

  Ménard, Henri A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DR ANTIGEN; SA ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN;

CONNECTIVE TISSUE DISEASE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SPONDYLOSIS; STATISTICAL ANALYSIS; WESTERN BLOTTING;

EID: 33847043567     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0401     Document Type: Short Survey

References (6)

1. Dejaco C et al. (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in RA. Arthritis Res Ther 19: R119
2. Ménard HA et al. (2000) Insights into RA derived from the Sa immune system. Arthritis Res Ther 2: 429-432
3. Boire G et al. (2005) Anti-Sa antibodies and antibodies against CCP are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7: R592-603
4. Asaga H et al. (11998) Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 243: 641-646
5. Hill JS et al. (2003) Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1 *0401 MHC class II molecule. J Immunol 171: 538-541
6. Auger I et al. (2005) Influence of HLA-DR genes on the production of RA-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52: 3424-3432